Michael H. Baumann

Pharmacology of “next generation” synthetic cathinones: The future is now

Michael H. Baumann, Kurt R. Lehner, Omar Bukhari, 2015 .

Neuropharmacology of replacement analogs of the designer drug 3,4-methylenedioxymethcathinone

Michael H. Baumann, Richard B. Rothman, John S. Partilla, 2015 .

(+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine Transporters

Michael H. Baumann, Richard B. Rothman, John S. Partilla, 2003, Journal of Pharmacology and Experimental Therapeutics.

3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings

Michael H. Baumann, Richard B. Rothman, R. Rothman, 2006, Psychopharmacology.

Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain

Michael H. Baumann, Richard B. Rothman, Robert D. Clark, 2008, Pharmacology Biochemistry and Behavior.

Dual dopamine/serotonin releasers as potential medications for stimulante and alcohol addictions

Michael H. Baumann, Richard B. Rothman, B. Blough, 2007, The AAPS Journal.

Development of Neurochemical Normalization (“Agonist Substitution”) Therapeutics for Stimulant Abuse: Focus on the Dopamine Uptake Inhibitor, GBR12909

Michael H. Baumann, Richard B. Rothman, Thomas E. Prisinzano, 2004 .